Lim S K, Sigmund C D, Gross K W, Maquat L E
Department of Human Genetics, Roswell Park Cancer Institute, Buffalo, New York 14263.
Mol Cell Biol. 1992 Mar;12(3):1149-61. doi: 10.1128/mcb.12.3.1149-1161.1992.
Human beta zero-thalassemic beta-globin genes harboring either a frameshift or a nonsense mutation that results in the premature termination of beta-globin mRNA translation have been previously introduced into the germ line of mice (S.-K. Lim, J.J. Mullins, C.-M. Chen, K. Gross, and L.E. Maquat, EMBO J. 8:2613-2619, 1989). Each transgene produces properly processed albeit abnormally unstable mRNA as well as several smaller RNAs in erythroid cells. These smaller RNAs are detected only in the cytoplasm and, relative to mRNA, are longer-lived and are missing sequences from either exon I or exons I and II. In this communication, we show by using genetics and S1 nuclease transcript mapping that the premature termination of beta-globin mRNA translation is mechanistically required for the abnormal RNA metabolism. We also provide evidence that generation of the smaller RNAs is a cytoplasmic process: the 5' ends of intron 1-containing pre-mRNAs were normal, the rates of removal of introns 1 and 2 were normal, and studies inhibiting RNA synthesis with actinomycin D demonstrated a precursor-product relationship between full-length mRNA and the smaller RNAs. In vivo, about 50% of the full-length species that undergo decay are degraded to the smaller RNAs and the rest are degraded to undetectable products. Exposure of erythroid cells that expressed a normal human beta-globin transgene to either cycloheximide or puromycin did not result in the generation of the smaller RNAs. Therefore, a drug-induced reduction in cellular protein synthesis does not reproduce this aspect of cytoplasmic mRNA metabolism. These data suggest that the premature termination of beta-globin mRNA translation in either exon I or exon II results in the cytoplasmic generation of discrete mRNA degradation products that are missing sequences from exon I or exons I and II. Since these degradation products appear to be the same for all nonsense codons tested, there is no correlation between the position of translation termination and the sites of nucleolytic cleavage.
携带移码或无义突变(导致β-珠蛋白mRNA翻译提前终止)的人类β⁰-地中海贫血β-珠蛋白基因先前已被导入小鼠种系(S.-K. 林、J.J. 马林斯、C.-M. 陈、K. 格罗斯和L.E. 马夸特,《欧洲分子生物学组织杂志》8:2613 - 2619, 1989年)。每个转基因在红细胞中产生加工正确但异常不稳定的mRNA以及几种较小的RNA。这些较小的RNA仅在细胞质中被检测到,相对于mRNA,它们寿命更长,并且缺失外显子I或外显子I和II的序列。在本通讯中,我们通过遗传学和S1核酸酶转录图谱分析表明,β-珠蛋白mRNA翻译的提前终止在机制上是异常RNA代谢所必需的。我们还提供证据表明,较小RNA的产生是一个细胞质过程:含内含子1的前体mRNA的5'端正常,内含子1和2的去除速率正常,并且用放线菌素D抑制RNA合成的研究表明全长mRNA与较小RNA之间存在前体 - 产物关系。在体内,约50%经历衰变的全长物种被降解为较小的RNA,其余的被降解为无法检测到的产物。将表达正常人类β-珠蛋白转基因的红细胞暴露于环己酰亚胺或嘌呤霉素中不会导致产生较小的RNA。因此,药物诱导的细胞蛋白质合成减少不会重现细胞质mRNA代谢的这一方面。这些数据表明,β-珠蛋白mRNA在外显子I或外显子II中的翻译提前终止导致在细胞质中产生离散的mRNA降解产物,这些产物缺失外显子I或外显子I和II的序列。由于对于所有测试的无义密码子,这些降解产物似乎都是相同的,因此翻译终止位置与核酸酶切割位点之间没有相关性。